一种磷脂药物坎普托神素-尼拉帕利联合体能自组装成超分子纳米管,用于联合癌症治疗。
A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy
Yaoji Li, Jingtian Liang, Yinan Zhang, XinRu Cheng, Wanqiu Li, Hanbing Wang, Hongli Chen, Hongfei Tian, Wenbin Nan, Zhijun Yang, Zhiguo Gao
Journal:JOURNAL OF CONTROLLED RELEASE
IF:12.4
DOI:10.1016/j.jconrel.2026.115181
PMID:
Published:2026-07-15
research field:呼吸生物学结构生物学微生物学
Abstract
Combination therapy with topoisomerase I and PARP inhibitors is promising for cancer treatment, yet its efficacy is often limited by mismatched pharmacokinetics and inefficient co-delivery. Here, we report a phospholipid-based single-molecule dual-drug conjugate, CNPC, in which camptothecin (CPT) and niraparib (NI) are covalently integrated into a choline glycerophosphate scaffold through redox-responsive linkers. The CNPC, enabled by their amphiphilic phospholipid architecture, spontaneously self-assemble in aqueous solution into stable supramolecular nanotubes (CNPC-NT) of ∼100 nm with a high overall drug loading of ∼46%. The CNPC-NT preserve the active lactone form of CPT, remain stable in plasma-related media, yet rapidly respond to high glutathione levels to simultaneously release both drugs. In vitro, CNPC-NT enhances DNA damage, apoptosis, and tumor cell killing compared with the parental CPT nanotubes. In vivo, CNPC-NT prolongs blood circulation with a longer half-life than liposomes, achieves effective tumor accumulation, and shows the strongest antitumor efficacy with good tolerability. This work establishes a phospholipid dual-drug strategy for synchronous combination therapy and provides a molecular design principle for self-assembling nanomedicines with stimulus-responsive release.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


